By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer “Equity: Every Patient. Every Day. Everywhere.” That was the theme for this year’s American Society for Clinical Oncology (ASCO) Annual Meeting. And, indeed, the theme of health equity [...]
By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung Cancer Unlocking the Biology of SCLC Patients with small cell lung cancer (SCLC) receive one-size-fits-all treatment because of limited knowledge about the biology of the disease. There are [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer Surgery has been the primary treatment for early stage non-small cell lung cancer (NSCLC). Unfortunately, many people have seen their cancer come back after surgery. Now researchers [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung Cancer and Daniel A. Saez, MSc, Navigator, Treatment & Trials, GO2 for Lung CancerNew Hope for Patients with KRASUntil recently, the KRAS mutation was considered un-targetable in most types [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung CancerA number of studies presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting related to the treatment of non-small cell lung cancer (NSCLC) with an EGFR mutation.Tagrisso [...]
By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung CancerChemotherapy has been the standard treatment option for Non-Small Cell Lung Cancer (NSCLC) without actionable biomarkers. Recently, immunotherapy treatments have been added into the treatment mix. Several studies presented [...]